A $475,000 price tag for a new cancer drug: crazy or meh?
Forget McGregor-Mayweather. The biotech world has been waiting for months to hear about Novartis’ pricing decision for Kymriah, its just-approved CAR-T therapy for cancer. That interest turned into anxiety days earlier when Gilead announced its purchase of Kite, given that Kite is expected to be the next company to market its own CAR-T treatment and Gilead…
Utah Standard News depends on the support of readers like you.
Good Journalism requires time, expertise, passion and money. We know you appreciate the coverage here. Please help us to continue as an alternative news website by becoming a subscriber or making a donation. To learn more about our subscription options or make a donation, click here.
To Advertise on UtahStandardNews.com, please contact us at: ed@utahstandardnews.com.
Comments - No Responses to “A $475,000 price tag for a new cancer drug: crazy or meh?”
Sure is empty down here...